How far does the pharmacological forgiveness of B/F/TAF extend—and where is its limit?
BETAF-RED, an investigator-initiated, publicly funded randomised phase 2 pilot trial, explored that question across daily, 3-, 2- and 1-day/week dosing. 🧵
BETAF-RED, an investigator-initiated, publicly funded randomised phase 2 pilot trial, explored that question across daily, 3-, 2- and 1-day/week dosing. 🧵